Fate Therapeutics (FATE) Competitors $1.21 0.00 (0.00%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.22 +0.01 (+1.16%) As of 08:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FATE vs. CYRX, ITOS, RAPT, OCGN, LRMR, ALMS, AUTL, ETHZ, ATXS, and ADCTShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include CryoPort (CYRX), iTeos Therapeutics (ITOS), Rapt Therapeutics (RAPT), Ocugen (OCGN), Larimar Therapeutics (LRMR), Alumis (ALMS), Autolus Therapeutics (AUTL), Flag Ship Acquisition (ETHZ), Astria Therapeutics (ATXS), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Its Competitors CryoPort iTeos Therapeutics Rapt Therapeutics Ocugen Larimar Therapeutics Alumis Autolus Therapeutics Flag Ship Acquisition Astria Therapeutics ADC Therapeutics Fate Therapeutics (NASDAQ:FATE) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings. Do analysts rate FATE or CYRX? Fate Therapeutics currently has a consensus price target of $3.30, indicating a potential upside of 172.73%. CryoPort has a consensus price target of $12.56, indicating a potential upside of 29.71%. Given Fate Therapeutics' higher possible upside, research analysts plainly believe Fate Therapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00CryoPort 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Is FATE or CYRX more profitable? CryoPort has a net margin of 37.21% compared to Fate Therapeutics' net margin of -2,025.05%. CryoPort's return on equity of -9.79% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-2,025.05% -50.95% -36.76% CryoPort 37.21%-9.79%-5.42% Do insiders & institutionals hold more shares of FATE or CYRX? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by insiders. Comparatively, 10.1% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings and valuation, FATE or CYRX? CryoPort has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M10.24-$186.26M-$1.45-0.83CryoPort$228.38M2.12-$114.76M$1.337.28 Does the media prefer FATE or CYRX? In the previous week, Fate Therapeutics had 1 more articles in the media than CryoPort. MarketBeat recorded 3 mentions for Fate Therapeutics and 2 mentions for CryoPort. CryoPort's average media sentiment score of 0.51 beat Fate Therapeutics' score of 0.48 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, FATE or CYRX? Fate Therapeutics has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. SummaryCryoPort beats Fate Therapeutics on 12 of the 17 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.55M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-0.8322.2886.8126.71Price / Sales10.24265.33538.97202.98Price / CashN/A46.3226.3031.09Price / Book0.439.9012.676.57Net Income-$186.26M-$52.45M$3.30B$276.78M7 Day Performance21.00%5.05%3.55%1.96%1 Month Performance19.80%10.61%6.79%9.11%1 Year Performance-62.42%25.03%72.30%31.60% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics3.912 of 5 stars$1.21flat$3.30+172.7%-62.4%$139.55M$13.63M-0.83550Gap UpHigh Trading VolumeCYRXCryoPort3.95 of 5 stars$9.41+2.3%$12.56+33.4%+22.7%$460.62M$228.38M7.081,186Positive NewsITOSiTeos TherapeuticsN/A$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790RAPTRapt Therapeutics3.5026 of 5 stars$26.62+0.9%$23.50-11.7%+88.4%$436.27M$1.53M0.0080High Trading VolumeOCGNOcugen1.7184 of 5 stars$1.45-0.7%$6.00+313.8%+75.2%$426.77M$4.05M0.0080LRMRLarimar Therapeutics2.9924 of 5 stars$3.38-33.6%$18.43+445.2%-26.8%$421.75MN/A-2.1730High Trading VolumeALMSAlumis3.6266 of 5 stars$3.95-2.5%$20.17+410.5%-58.7%$421.46MN/A0.00N/ANews CoverageAUTLAutolus Therapeutics3.564 of 5 stars$1.59+1.9%$9.12+473.6%-59.5%$415.18M$10.12M-1.89330ETHZFlag Ship AcquisitionN/A$2.48-1.2%N/AN/A$412.72MN/A0.007ATXSAstria Therapeutics2.6358 of 5 stars$7.36+0.8%$30.20+310.3%-36.6%$411.98MN/A-3.6630ADCTADC Therapeutics2.93 of 5 stars$4.02+10.0%$7.75+93.0%+24.7%$410.62M$70.84M-2.56310News CoveragePositive NewsAnalyst Revision Related Companies and Tools Related Companies CryoPort Alternatives iTeos Therapeutics Alternatives Rapt Therapeutics Alternatives Ocugen Alternatives Larimar Therapeutics Alternatives Alumis Alternatives Autolus Therapeutics Alternatives Flag Ship Acquisition Alternatives Astria Therapeutics Alternatives ADC Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FATE) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
